These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32906608)

  • 1. Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria.
    Wennmann M; Hielscher T; Kintzelé L; Menze BH; Langs G; Merz M; Sauer S; Kauczor HU; Schlemmer HP; Delorme S; Goldschmidt H; Weinhold N; Hillengass J; Weber MA
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32906608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns.
    Wennmann M; Hielscher T; Kintzelé L; Menze BH; Langs G; Merz M; Sauer S; Kauczor HU; Schlemmer HP; Delorme S; Goldschmidt H; Weinhold N; Hillengass J; Weber MA
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis.
    Ludwig H; Kainz S; Schreder M; Zojer N; Hinke A
    EClinicalMedicine; 2023 Apr; 58():101910. PubMed ID: 36969337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.
    Merz M; Hielscher T; Wagner B; Sauer S; Shah S; Raab MS; Jauch A; Neben K; Hose D; Egerer G; Weber MA; Delorme S; Goldschmidt H; Hillengass J
    Leukemia; 2014 Sep; 28(9):1902-8. PubMed ID: 24535407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
    Wennmann M; Goldschmidt H; Mosebach J; Hielscher T; Bäuerle T; Komljenovic D; McCarthy PL; Merz M; Schlemmer HP; Raab MS; Sauer S; Delorme S; Hillengass J
    Br J Haematol; 2022 Oct; 199(1):65-75. PubMed ID: 35608264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.
    Hillengass J; Fechtner K; Weber MA; Bäuerle T; Ayyaz S; Heiss C; Hielscher T; Moehler TM; Egerer G; Neben K; Ho AD; Kauczor HU; Delorme S; Goldschmidt H
    J Clin Oncol; 2010 Mar; 28(9):1606-10. PubMed ID: 20177023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
    Dutoit JC; Vanderkerken MA; Verstraete KL
    Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial.
    Mesguich C; Hulin C; Latrabe V; Asselineau J; Bordenave L; Perez P; Hindie E; Marit G
    JMIR Res Protoc; 2020 Sep; 9(9):e17850. PubMed ID: 32909953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
    Walker R; Barlogie B; Haessler J; Tricot G; Anaissie E; Shaughnessy JD; Epstein J; van Hemert R; Erdem E; Hoering A; Crowley J; Ferris E; Hollmig K; van Rhee F; Zangari M; Pineda-Roman M; Mohiuddin A; Yaccoby S; Sawyer J; Angtuaco EJ
    J Clin Oncol; 2007 Mar; 25(9):1121-8. PubMed ID: 17296972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Whole-body MRI in children with langerhans cell histiocytosis for the evaluation of the skeletal system].
    Steinborn M; Wörtler K; Nathrath M; Schöniger M; Hahn H; Rummeny EJ
    Rofo; 2008 Jul; 180(7):646-53. PubMed ID: 18561067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma.
    Narquin S; Ingrand P; Azais I; Delwail V; Vialle R; Boucebci S; Tasu JP
    Diagn Interv Imaging; 2013 Jun; 94(6):629-36. PubMed ID: 23683788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response.
    Park HY; Kim KW; Yoon MA; Lee MH; Chae EJ; Lee JH; Chung HW; Yoon DH
    Cancer Imaging; 2020 Jan; 20(1):14. PubMed ID: 32000858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of whole-body 64-slice multidetector computed tomography in treatment planning for multiple myeloma.
    Razek AA; Ezzat A; Azmy E; Tharwat N
    Radiol Med; 2013 Aug; 118(5):799-805. PubMed ID: 22986700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy.
    Dinter DJ; Neff WK; Klaus J; Böhm C; Hastka J; Weiss C; Schoenberg SO; Metzgeroth G
    Ann Hematol; 2009 May; 88(5):457-64. PubMed ID: 18941746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
    Ho PJ; Moore E; Wellard C; Quach H; Blacklock H; Harrrison SJ; MacDonald EJ; McQuilten ZK; Wood EM; Mollee P; Spencer A
    Br J Haematol; 2024 Jul; ():. PubMed ID: 38965706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
    Catalano OA; Daye D; Signore A; Iannace C; Vangel M; Luongo A; Catalano M; Filomena M; Mansi L; Soricelli A; Salvatore M; Fuin N; Catana C; Mahmood U; Rosen BR
    Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.
    Dimopoulos MA; Hillengass J; Usmani S; Zamagni E; Lentzsch S; Davies FE; Raje N; Sezer O; Zweegman S; Shah J; Badros A; Shimizu K; Moreau P; Chim CS; Lahuerta JJ; Hou J; Jurczyszyn A; Goldschmidt H; Sonneveld P; Palumbo A; Ludwig H; Cavo M; Barlogie B; Anderson K; Roodman GD; Rajkumar SV; Durie BG; Terpos E
    J Clin Oncol; 2015 Feb; 33(6):657-64. PubMed ID: 25605835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.